European Monitoring Centre for Drugs and Drug Addiction

One of the two EMCDDA agency buildings in Lisbon

Error creating thumbnail:

Palacete do Relógio – one of the two agency buildings in Lisbon

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is an agency of the European Union tasked with providing the EU and its member states with a factual overview of European drug problems and a solid evidence base to support the drugs debate. Today, it offers policymakers the data they need for formulating informed drug laws and strategies. It also helps professionals and practitioners working in the field to identify best practices and new areas of concern.

History

The EMCDDA was established in 1993 and began its operations in Lisbon, Portugal, in 1995. Its creation was part of a broader strategy by the EU to address and coordinate action against drug abuse and trafficking within its member states. The agency was set up in response to the increasing drug problems of the 1980s and early 1990s, recognizing the need for a centralized hub to collect, analyze, and disseminate information about drugs and drug addiction.

Mission

The mission of the EMCDDA is to provide the EU and its member states with high-quality, objective, reliable, and comparable information at European level concerning drugs and drug addiction and their consequences. This comprehensive overview assists in the formulation of coherent national and EU drug policies, enhancing the ability to respond rapidly to emerging trends and patterns.

Activities

The core activities of the EMCDDA include the collection and analysis of data on drug use and public health issues, as well as drug law and policies in member states. It publishes an annual report on the state of the drugs problem in Europe, which is widely recognized as a key reference in the field. The EMCDDA also develops and maintains a number of key indicators to monitor drug trends over time, including the European Drug Report, which provides an analysis of the latest data on drug use and its consequences.

Key Indicators

• General Population Surveys (GPS): Surveys conducted to assess drug use among the general population.
• Problem Drug Use (PDU): Estimates of the number of people engaging in the use of drugs that are considered particularly harmful (e.g., injecting drug use).
• Treatment Demand Indicator (TDI): Data on the number and characteristics of people seeking treatment for drug use.
• Drug-Related Deaths (DRD): Statistics on deaths directly attributable to drug use.
• Infectious Diseases: Monitoring of infectious diseases among drug users, particularly HIV and hepatitis.

Governance

The EMCDDA is governed by a Management Board, which is composed of one representative from each EU member state, two representatives from the European Commission, and two representatives appointed by the European Parliament. The Management Board is responsible for ensuring the agency's work is aligned with the EU's priorities and policies in the field of drugs.

Impact

The work of the EMCDDA has a significant impact on drug policy and practice across Europe. By providing evidence-based data and analysis, the agency helps to shape policies that aim to reduce drug-related harm and promote public health. Its research and reports are used by policymakers, researchers, health professionals, and NGOs to better understand and respond to the challenges posed by drug use and addiction.

Challenges and Future Directions

The EMCDDA faces ongoing challenges, including the emergence of new psychoactive substances, the evolving landscape of drug trafficking and use due to globalization and technological advances, and the need to address drug-related harm in a comprehensive and humane manner. The agency continues to adapt its methodologies and expand its data sources to effectively monitor and analyze these trends.